Table III.
Bias (%) | RRMSE (%) | |||||||
---|---|---|---|---|---|---|---|---|
1% | 5% | 10% | 20% | 1% | 5% | 10% | 20% | |
θ 0 | −1.4 | −0.4 | −0.3 | −0.2 | 8.3 | 2.1 | 1.5 | 1.1 |
θ 1 | −0.1 | 0.2 | −0.1 | 0.4 | 6.4 | 6.3 | 6.6 | 6.9 |
γ | 0.9 | 1.4 | 0.7 | 0.8 | 9 | 9 | 9.6 | 9.4 |
K on | 2.7 | 1.9 | 3 | 2.5 | 18.6 | 18.2 | 19.8 | 20.5 |
E max | 2.3 | 1.7 | 2.2 | 2.6 | 15 | 14.7 | 15.8 | 14.4 |
EC50 | 13.3 | 10.3 | 11.7 | 9.6 | 51.8 | 49.7 | 53 | 47.1 |
ω 00 | −0.6 | −0.8 | −1.3 | −2.2 | 3.2 | 3.2 | 3.4 | 3.8 |
ω 11 | −1 | −1.2 | −1.6 | −2.1 | 5 | 5.2 | 5.2 | 6 |
θ 0 baseline disease state, θ 1 rate of disease progression, γ magnitude of the placebo effect, K on onset rate of the placebo effect, E max maximum disease-modifying effect, EC 50 concentration at which 50% of the maximum effect, ω 00 standard deviation of interindividual variability on baseline, ω 11 standard deviation of interindividual variability on rate of progression